Citius Oncology (CTOR) Non Operating Income (2023 - 2026)

Citius Oncology (CTOR) has reported Non Operating Income for 4 consecutive years, with -$314376.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non Operating Income fell 95.56% year-over-year to -$314376.0 in Q2 2026; TTM through Jun 2026 was $1.4 million, a 58.1% decrease from a year earlier, with the FY2025 full-year figure at -$181659.0, changed N/A from the prior year.
• Non Operating Income was -$314376.0 for Q2 2026 at Citius Oncology, down from $1.8 million in the prior quarter.
• Over five years, Non Operating Income peaked at $2.2 million in Q3 2023 and troughed at -$314376.0 in Q2 2026.
• A 4-year average of $638417.1 and a median of $697338.5 in 2024 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income decreased 0.18% in 2024 and sank 125.26% in 2025, its largest moves.
• Over 4 years, Non Operating Income stood at $2.2 million in 2023, then tumbled by 70.47% to $636419.0 in 2024, then plunged by 102.76% to -$17553.0 in 2025, then slumped by 1691.01% to -$314376.0 in 2026.
• The last three Non Operating Income figures came in at -$314376.0 (Q2 2026), $1.8 million (Q1 2026), and -$17553.0 (Q4 2025), per Business Quant data.